Oscar Health (OSCR) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Oscar Health will report Q4 2025 results before the market opens on Feb 10, 2026 (8:00 AM ET); analysts expect a loss of ($0.84) per share and about $3.12 billion in revenue.
• In the prior quarter the company posted ($0.53) EPS (beating estimates) and $2.93 billion in revenue (missing expectations), with revenue up 23.2% year‑over‑year but continuing losses reflected in a negative net margin and negative return on equity.
• Market sentiment is cautious: the average analyst rating is "Reduce" with a $17 price target, the stock trades near $14 (market cap ≈ $3.7B), and insiders have recently sold shares.

Oscar Health (NYSE:OSCR - Get Free Report) is expected to announce its Q4 2025 results before the market opens on Tuesday, February 10th. Analysts expect the company to announce earnings of ($0.84) per share and revenue of $3.1234 billion for the quarter. Individuals can check the company's upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 10, 2026 at 8:00 AM ET.

Oscar Health (NYSE:OSCR - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.53) EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.02. The business had revenue of $2.93 billion during the quarter, compared to analysts' expectations of $3.09 billion. Oscar Health had a negative net margin of 2.16% and a negative return on equity of 21.50%. The business's quarterly revenue was up 23.2% on a year-over-year basis. During the same period last year, the company posted ($0.22) earnings per share. On average, analysts expect Oscar Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Oscar Health Price Performance

OSCR opened at $14.00 on Tuesday. Oscar Health has a 1 year low of $11.20 and a 1 year high of $23.80. The firm's fifty day moving average price is $15.98 and its two-hundred day moving average price is $16.81. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.92 and a quick ratio of 0.92. The company has a market capitalization of $3.71 billion, a price-to-earnings ratio of -12.50 and a beta of 1.90.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. UBS Group raised shares of Oscar Health from a "sell" rating to a "neutral" rating and lifted their price target for the stock from $12.00 to $17.00 in a report on Friday, January 9th. Wells Fargo & Company lowered their target price on Oscar Health from $14.00 to $11.00 and set an "underweight" rating on the stock in a research note on Thursday, November 13th. The Goldman Sachs Group assumed coverage on shares of Oscar Health in a research report on Tuesday, October 14th. They set a "neutral" rating and a $17.00 target price for the company. Wall Street Zen lowered Oscar Health from a "hold" rating to a "sell" rating in a report on Saturday, December 6th. Finally, Stephens began coverage on Oscar Health in a research note on Thursday, December 11th. They set an "equal weight" rating and a $17.00 price objective on the stock. One analyst has rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Reduce" and an average price target of $17.00.

Insider Activity

In other Oscar Health news, insider Adam Mcananey sold 1,852 shares of the company's stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $16.59, for a total value of $30,724.68. Following the transaction, the insider directly owned 179,241 shares in the company, valued at $2,973,608.19. This represents a 1.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Janet Liang sold 7,338 shares of the company's stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $16.59, for a total transaction of $121,737.42. Following the completion of the transaction, the insider owned 172,527 shares in the company, valued at approximately $2,862,222.93. This trade represents a 4.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 483,307 shares of company stock valued at $7,635,300 over the last 90 days. Company insiders own 25.11% of the company's stock.

Hedge Funds Weigh In On Oscar Health

Institutional investors and hedge funds have recently bought and sold shares of the stock. Strs Ohio bought a new position in Oscar Health during the 1st quarter valued at approximately $30,000. Jones Financial Companies Lllp grew its holdings in shares of Oscar Health by 7,473.3% during the 1st quarter. Jones Financial Companies Lllp now owns 2,272 shares of the company's stock worth $30,000 after acquiring an additional 2,242 shares during the period. Quarry LP raised its position in shares of Oscar Health by 439.8% in the 3rd quarter. Quarry LP now owns 1,803 shares of the company's stock worth $34,000 after acquiring an additional 1,469 shares in the last quarter. Binnacle Investments Inc bought a new stake in shares of Oscar Health during the second quarter valued at approximately $75,000. Finally, National Bank of Canada FI bought a new position in Oscar Health in the third quarter worth $81,000. 75.70% of the stock is currently owned by institutional investors.

About Oscar Health

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company's primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.